Welcome to our dedicated page for Akebia Therapeutics news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeutics stock.
Akebia Therapeutics, Inc. (NASDAQ: AKBA) is a fully integrated biopharmaceutical company headquartered in Cambridge, Massachusetts. Focused on delivering innovative therapies for patients with kidney disease, Akebia leverages hypoxia-inducible factor (HIF) biology in its product development. The company's lead product candidate, vadadustat, is an investigational oral therapy aimed at treating anemia related to chronic kidney disease (CKD) in both non-dialysis and dialysis patients. Akebia's global phase 3 program for vadadustat includes the PRO2TECT studies for non-dialysis patients and the INNO2VATE studies for dialysis-dependent patients. Vadadustat has received approval for the treatment of anemia due to CKD in multiple countries including Japan, Europe, and Australia, and is awaiting U.S. FDA approval with a PDUFA date set for March 27, 2024.
In addition to vadadustat, Akebia's portfolio includes Auryxia (ferric citrate), a medicine approved in the U.S. for the control of serum phosphorus levels in adult patients with dialysis-dependent CKD and the treatment of iron deficiency anemia in adult patients with non-dialysis-dependent CKD. Auryxia continues to show robust performance, with 2023 net product revenues totaling $170.3 million.
Akebia recently strengthened its financial position by securing a loan facility from BlackRock, providing up to $55 million in borrowing capacity. This move is geared towards supporting the potential U.S. launch of vadadustat, which Akebia anticipates will transform the company and provide a new oral treatment option for anemia in dialysis patients.
Current projects include exploring new pipeline programs targeted at acute care settings, such as acute kidney injury and acute respiratory distress syndrome, as well as retinopathy of prematurity in neonates.
With significant partnerships, a strong pipeline, and strategic financial maneuvers, Akebia Therapeutics continues to be a key player in the biopharmaceutical space, dedicated to bettering the lives of individuals affected by kidney disease.
Akebia Therapeutics (Nasdaq: AKBA) plans to release its financial results for Q2 2022 on August 4, 2022, after market closure. The company will conduct a conference call at 4:30 p.m. ET on the same day to discuss these results and provide a business update. Listeners can join the call by dialing (833) 630-1955 (domestic) or (412) 317-1836 (international), or access the live webcast via the Investors section of Akebia's website. The call replay will be available from August 4 through August 10, 2022.
On July 5, 2022, Akebia Therapeutics (Nasdaq: AKBA) announced the grant of stock options to two newly-hired employees, totaling 4,000 shares. These options were awarded to incentivize employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price of $0.35, which matches the closing stock price on the grant date. The options vest over four years, with 25% vesting on the first anniversary and the remainder vesting quarterly, contingent on continued service. Akebia focuses on therapeutics for kidney disease.
Akebia Therapeutics (Nasdaq: AKBA) announced the termination of its collaboration with Otsuka Pharmaceutical regarding vadadustat, with a settlement fee of $55 million to be received by Akebia. This decision allows Akebia to regain rights to vadadustat in multiple regions, including the U.S., Europe, China, and others. The company aims to pursue regulatory approval for vadadustat, especially after receiving a Complete Response Letter from the FDA. Akebia's CEO expressed optimism about the product's potential for treating anemia in chronic kidney disease patients.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) will be presenting at the Jefferies Healthcare Conference on June 9, 2022, at 10:30 a.m. ET. CEO John Butler will represent the company, which focuses on improving the lives of those affected by kidney disease. The conference is scheduled for June 8-10, 2022, in New York. Investors can access a live webcast of the presentation on the company’s website, with a replay available for 90 days after. Akebia, established in 2007 and based in Cambridge, Massachusetts, is dedicated to developing therapeutics for kidney disease.
Akebia Therapeutics (Nasdaq: AKBA) announced the grant of stock options to three new employees totaling 14,000 shares on May 31, 2022. The options, which have an exercise price of $0.37 per share, align with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting quarterly, contingent on continued employment. Akebia, based in Cambridge, Massachusetts, focuses on biopharmaceutical solutions for kidney disease.
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company dedicated to improving the lives of those affected by kidney disease, will have CEO John Butler participate in a fireside chat at the H.C. Wainwright Global Investment Conference, scheduled for May 23–26, 2022. An audio replay of the chat will be accessible through Akebia's investor relations webpage starting on May 24 for approximately 90 days. Founded in 2007 and based in Cambridge, Massachusetts, Akebia focuses on developing and commercializing therapeutics for kidney disease.
Akebia Therapeutics (AKBA) reported a 36% increase in net Auryxia revenue, totaling $41.4 million in Q1 2022. Total revenue reached $61.7 million, up from $52.3 million a year earlier. The company provided 2022 revenue guidance for Auryxia of $165 million to $170 million. Despite a Complete Response Letter from the FDA regarding vadadustat, Akebia aims to focus on Auryxia's commercial success and explore earlier-stage assets. The cash position stands at $174.6 million.
Akebia Therapeutics (Nasdaq: AKBA) plans to release its first-quarter financial results for 2022 on May 9, 2022, after market close. The company will hold a conference call at 4:30 p.m. ET to discuss these results and provide a business update. Participants can join the call via phone or listen live on Akebia's website. A replay will be available shortly after the call concludes, lasting until May 15, 2022. Akebia focuses on developing therapeutics for individuals affected by kidney disease.
On April 6, 2022, Akebia Therapeutics (Nasdaq: AKBA) announced its participation in the National Kidney Foundation Spring Clinical Meetings 2022 in Boston, scheduled for April 6-10, 2022. The company will present three significant posters focusing on real-world healthcare costs, adherence to phosphate binders, and thrombotic events in dialysis-dependent patients. Notably, Vadadustat, an investigational drug for chronic kidney disease anemia, received a complete response letter from the FDA on March 29, 2022, while still under review by the European Medicines Agency.
On April 4, 2022, Akebia Therapeutics (Nasdaq: AKBA) announced the grant of stock options to nine newly-hired employees, totaling 53,000 shares. Each option has an exercise price of $0.72, matching the closing stock price on the grant date. These options vest over four years, with 25% vesting on the first anniversary and the remainder quarterly, contingent on continued employment. The grant complies with Nasdaq Listing Rule 5635(c)(4) and aims to strengthen employee retention and incentivize performance.
FAQ
What is the current stock price of Akebia Therapeutics (AKBA)?
What is the market cap of Akebia Therapeutics (AKBA)?
What does Akebia Therapeutics, Inc. specialize in?
What is vadadustat?
Is vadadustat approved by the FDA?
What are Akebia’s approved products?
What recent financial moves has Akebia made?
What is Auryxia?
Where is Akebia Therapeutics located?
When was Akebia founded?
What are Akebia’s new pipeline programs?
How has Auryxia performed financially?
